The protective effect of selenoprotein M on non-alcoholic fatty liver disease: the role of the AMPKα1-MFN2 pathway and Parkin mitophagy

Non-alcoholic fatty liver disease (NAFLD) is related to a dysregulation of mitophagy, a process that is not fully understood. Parkin-related mitophagy can sustain mitochondrial homeostasis and hepatocyte viability. Herein, we report that selenoprotein M (SELENOM) plays a central role in maintaining mitophagy in high-fat diet (HFD)-mediated NAFLD. We show that SELENOM was significantly downregulated in the liver of HFD-fed mice. SELENOM deletion aggravated HFD-mediated hepatic steatosis, inflammation, and fibrosis; accompanied by enhanced fatty acid oxidation and oxidative stress in the liver. Molecular analyses show that lipotoxicity was related to increased mitochondrial apoptosis as evidenced by enhanced mitochondrial ROS production, and attenuation of mitochondrial potential in the liver of HFD-fed SELENOM-/- mice. Additionally, SELENOM deletion reduced mitophagy and aggravated hepatic injury in NAFLD. Mechanistically, SELENOM overexpression activated Parkin-mediated mitophagy to reduce mitochondrial apoptosis and remove HFD-damaged mitochondria. We further found that SELENOM regulates Parkin expression via the AMPK alpha 1-MFN2 pathway; blockade of AMPK alpha 1 prevented SELENOM activation of Parkin-mediated mitophagy. Our work identified SELENOM downregulation as a possible explanation for the defective mitophagy in NAFLD. Thus, targeting SELENOM may be potential new therapeutic modalities for NAFLD treatment.